10x Genomics, Inc. is trading 8.2% up at $34.76 in pre-market, extending its strong recent rebound over the past week. - The move likely reflects follow-through momentum and thin pre-market liquidity. - This follows recent company-specific developments, including its Proteintech Genomics acquisition (June 9, 2026) and a collaboration with Cleveland Clinic to advance bladder cancer research (June 17, 2026), in addition to its Q1 2026 results (May 7, 2026).